Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aerie ROCKETS On Glaucoma Data

This article was originally published in Scrip

Executive Summary

Aerie Pharmaceuticals Inc. has reported positive results from its second Phase III trial for Rhopressa (AR-13324), which is being tested to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The news sent the company's share price soaring by almost 70% (Sep. 17), and Aerie expects to file its NDA for Rhopressa in mid-2016.

Advertisement

Related Content

Aerie's M&A Potential Rises As Roclatan Passes Second Phase III Glaucoma Test
Keeping Track: New Drugs For Glaucoma, Sickle Cell Submitted; IDegLira, Brineura Reviews Extended; Keytruda Advances In First-Line NSCLC

Topics

Advertisement
UsernamePublicRestriction

Register

SC029790

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel